| Ticker: | FBIOX |
| Manager: | Rajiv Kaul |
| Manager Since: | 10/05 |
| NAV (06/18/2013): | 143.45 |
| Objective: | Equity - Sector Health |
| Peer: | HL MG |
| Net Assets ($mil): | 4896.77 |
| Inception: | 12/16/1985 |
FBIOX : Description
Incepted in December 1985 and managed by the Fidelity Group, the objective of this fund is to seek capital appreciation. It normally invests at least 80% of assets in common stocks of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund offers dividends and capital gains in the month of April and December.
FBIOX : Composition - 05/13
| Stocks | 99.31% |
| Foreign Stocks | 1.49% |
| Cash | 7.92% |
| Bonds | 0.00% |
| Foreign Bonds | 0.00% |
| Preferred | 0.24% |
| Convertible | 0.17% |
| Other | -7.65% |
| Foreign Hedged | 0.00% |
FBIOX : Style Analysis - 05/13
| Large Growth | 51.27% |
| Large Value | 0.00% |
| Small Growth | 0.00% |
| Small Value | 0.00% |
| Foreign Stock | 51.27% |
| Emerging Market | 0.00% |
| Precious Metals | 0.00% |
| Intermediate Bond | 0.00% |
| High Yield Bond | 0.00% |
| Foreign Bond | 0.00% |
FBIOX : Risk Analysis
| Beta v. S&P 500 | 1.35 |
| Beta v. EAFE | -0.18 |
| Beta v. Barclays Agg Bond | 1.28 |
| Alpha 3 Yr | 13.26 |
| Alpha 5 Yr | 15.70 |
| R-Sq 3 Yr | 0.66 |
| R-Sq 5 Yr | 0.45 |
| Std Dev 3 Yr | 19.21 |
| Std Dev 5 Yr | 20.75 |
| Sharpe 3 Yr | 1.53 |
| Sharpe 5 Yr | 1.03 |
FBIOX : Fees
| Expense Ratio | 0.81 |
| % Max Load | NA |
| % Min Load | NA |
| % Deferred Load | NA |
| % Redemption | 0.75 |
| % Max 12 B1 Fee | 0.00 |
| % Max Mgt Fee | 0.56 |
FBIOX : Purchase Choices:
| Min Initial Investment | 2500 |
| Min Subsequent Investment | 0 |
FBIOX : Returns Analysis - Annual
| 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | YTD | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NAV ($) | 51.48 | 57.65 | 62.70 | 64.96 | 66.68 | 59.11 | 65.49 | 72.96 | 86.10 | 109.99 | 143.45 |
| Total Return (%) | 32.92 | 11.98 | 8.76 | 3.60 | 2.64 | -11.35 | 10.79 | 11.40 | 18.18 | 36.59 | 27.37 |
| Annual Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Relative Performance | |||||||||||
| Rel Performance-S&P500(%) | 42.29 | 11.12 | 38.69 | -121.92 | -28.47 | 256.55 | -156.28 | -36.58 | 160.82 | 205.98 | 146.28 |
| Rel Performance-Obj.Ret.(%) | 23.75 | 32.05 | -2.03 | -1.31 | -62.17 | 123.44 | -110.84 | 33.81 | 104.33 | 173.59 | 77.89 |
| Ret.Quintile vs Obj(1 is best) | 2 | 2 | 4 | 3 | 5 | 1 | 5 | 2 | 1 | 1 | 1 |
| Turnover, Yields, and Gains | |||||||||||
| Fund Assets Net($mil) | 1,853 | 1,850 | 1,679 | 1,464 | 1,188 | 1,197 | 1,051 | 1,038 | 1,341 | 2,731 | 4,897 |
| Annual Turnover (%) | 73.00 | 29.00 | 19.00 | 63.00 | 70.00 | 143.00 | 55.00 | 109.00 | 119.00 | 106.00 | 42.00 |
| Annual Dividend Paid ($) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Annual Capital Gains Paid($) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 6.48 | 0.05 |
FBIOX : Returns Analysis - Trailing Total Return
| 1 Month | 3 Month | 6 Month | YTD | 1 Year | 3 Year | 5 Year | 10 Year | 15 Year | 20 Year | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Return (through 05/13) | 5.82% | 18.68% | 31.53% | 27.37% | 45.47% | 27.35% | 19.18% | 13.35% | 11.32% | 11.96% |
| Ret. Percentile vs. Obj. (1 is best) | 6 | 1 | 1 | 5 | 1 | 1 | 4 | 16 | 8 | 30 |
FBIOX : Stock Portfolio Snapshot - 05/13
| Average Price/Earnings | 40.53 |
| Average Price/Book | 5.64 |
| Average EPS Growth | 15.35 |
| Average Market Value | 28,428.00 |
FBIOX : Stock Sector Breakout - 05/13
FBIOX : Top Holdings - 05/13
| Name | Weight | Shares |
|---|---|---|
| GILEAD SCIENCES INC | 13.77 | 4,923,072 |
| AMGEN INC | 12.81 | 3,866,495 |
| BIOGEN IDEC INC | 7.39 | 1,327,956 |
| REGENERON PHARMACEUTICALS | 5.79 | 879,087 |
| BIOMARIN PHARMACEUTICAL | 2.46 | 1,358,328 |
| ONYX PHARMACEUTICALS INC | 3.61 | 1,281,245 |
| MEDIVATION INC | 3.49 | 1,793,896 |
| VERTEX PHARMACEUTICALS INC | 2.73 | 1,842,018 |
| CELGENE CORP | 4.66 | 1,589,001 |